Sunitinib (Synonyms: 舒尼替尼; SU 11248)

目录号: HY-10255A 纯度: 98.96%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Sunitinib (SU 11248) 是一种多靶点受体酪氨酸激酶抑制剂，抑制 VEGFR2 和 PDGFRβ 的 IC₅₀ 分别为 80 nM 和 2 nM。Sunitinib 是ATP 竞争性抑制剂，可通过抑制自身磷酸化和随后的 RNase 激活来有效抑制 Ire1α 的磷酸化。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Sunitinib Chemical Structure

CAS No. : 557795-19-4

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥715	In-stock
100 mg	￥650	In-stock
200 mg	￥950	In-stock
500 mg	￥1500	In-stock
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Sunitinib:

MCE 顾客使用本产品发表的 58 篇科研文献

RT-PCR

IHC

Cell Viability Assay

: Sunitinib purchased from MCE. Usage Cited in: J Pharm Anal. 2023 Apr 19.; Sunitinib (3 μM; 24 h) increases the expression of γ-H2Ax and Temozolomide (TMZ; 10 μM; 24 h) increases the induction of Sunitinib, in T98G cells.

: Sunitinib purchased from MCE. Usage Cited in: J Pharm Anal. 2023 Apr 19.; Sunitinib (0-100 μM; 72 h) induces significant cell death in T98G cells.

: Sunitinib purchased from MCE. Usage Cited in: J Pharm Anal. 2023 Apr 19.; Sunitinib (3 μM; 24 h) increases the expression of γ-H2Ax and Temozolomide (TMZ; 10 μM; 24 h) increases the induction of Sunitinib, in T98G cells.

: Sunitinib purchased from MCE. Usage Cited in: Theranostics. 2018 Jul 30;8(15):4262-4278. [Abstract]; BV2 cells are pretreated with 0.1% DMSO (Ctrl), JuA (25 µM) or JuA (25 µM) with the indicated antagonist of RTKs (Dovitinib at 1 µM, Gefinitib at 2.5 µM, Sunitinib at 2.5 µM and LDC1267 at 1 µM) for 30 min, followed by administration of Aβ42 (5 μM) for 12 h.

: Sunitinib purchased from MCE. Usage Cited in: EBioMedicine. 2018 Nov;37:344-355. [Abstract]; Sutent (Sunitinib Malate) treatment decreases lipid accumulation in adipose and liver tissues and increases UCP1 expression in brown adipose tissue. Western blot analysis of UCP1 protein expression level in mouse brown adipose.

: Sunitinib purchased from MCE. Usage Cited in: EBioMedicine. 2018 Nov;37:344-355. [Abstract]; Sutent (Sunitinib Malate) treatment decreases lipid accumulation in adipose and liver tissues and increases UCP1 expression in brown adipose tissue. Representative images of immunohistochemistry stainining of UCP1 in BAT.

: Sunitinib purchased from MCE. Usage Cited in: Oncotarget. 2017 Jul 27;8(56):95116-95134. [Abstract]; Abemaciclib causes increased PARP cleavage in RCC. In Caki-1 cells Abemaciclib exposure results in increased PARP cleavage. This effect is more rapid and pronounced when Abemaciclib is combined with Sunitinib.

: Sunitinib purchased from MCE. Usage Cited in: Oncotarget. 2017 Jul 27;8(56):95116-95134. [Abstract]; Abemaciclib causes increased PARP cleavage in RCC. In 786-O cells Abemaciclib exposure results in increased PARP cleavage. This effect is more rapid and pronounced when Abemaciclib is combined with Sunitinib.

: Sunitinib purchased from MCE. Usage Cited in: Oncotarget. 2017 Nov 15;8(67):111110-111118. [Abstract]; In cell EC50 determination of CHMFL-KIT-031 with parental Colo320DM (KIT wt) and KIT V559D overexpressed Colo320DM cells.

: Sunitinib purchased from MCE. Usage Cited in: J Med Chem. 2016 Sep 22;59(18):8456-72. [Abstract]; Effect of compounds 1 (Imatinib), 2 (Sunitinib), and 35 on cKIT mediated signaling pathways in GIST-T1 and GIST-5R cancer cell lines.

: Sunitinib purchased from MCE. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]; The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/Sunitinib (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by Western blot (with GAPDH as internal control).

: Sunitinib purchased from MCE. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]; The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/Sunitinib (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by RT-PCR (with β-actin as internal control).

Sunitinib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 VEGFR 亚型特异性产品:

查看所有亚型

VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

查看 PDGFR 亚型特异性产品:

查看所有亚型

PDGFR PDGFRβ PDGFRα

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively^[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation^[2].

IC₅₀ & Target^[1]

VEGFR2

80 nM (IC₅₀)

PDGFRβ

2 nM (IC₅₀)

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A-375	IC₅₀	11.58 μM Compound: SU-11248	Cytotoxicity against human A375 cells after 48 hrs by MTT assay Cytotoxicity against human A375 cells after 48 hrs by MTT assay	[PMID: 22483608]
A-375	IC₅₀	5400 nM Compound: Sunitinib	Toxicity against human A375 cells after 72 hrs by cell titer-blue assay Toxicity against human A375 cells after 72 hrs by cell titer-blue assay	[PMID: 19654408]
A-431	IC₅₀	172.1 nM Compound: Sunitinib	Inhibition of EGFR in human A431 cells compound pretreated for 60 min before EGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method Inhibition of EGFR in human A431 cells compound pretreated for 60 min before EGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method	[PMID: 25882519]
A-431	IC₅₀	172.1 nM Compound: Sunitinib	Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay	[PMID: 24890652]
A-431	IC₅₀	172.1 μM Compound: 4	Inhibition of EGFR tyrosine kinase activity in EGF-stimulated human A431 cells after 60 mins by ELISA Inhibition of EGFR tyrosine kinase activity in EGF-stimulated human A431 cells after 60 mins by ELISA	[PMID: 22204741]
A-431	IC₅₀	172.1 μM Compound: Sunitinib	Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA	[PMID: 23434139]
A-431	IC₅₀	172.1 μM Compound: SU11248	Inhibition of EGFR in human A431 cells pretreated for 60 mins measured after 1 hr by ELISA Inhibition of EGFR in human A431 cells pretreated for 60 mins measured after 1 hr by ELISA	[PMID: 22739090]
A-431	IC₅₀	172.1 μM Compound: 4	Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA	[PMID: 20403700]
A-431	IC₅₀	172.1 μM Compound: 4	Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis	[PMID: 23375090]
A498	IC₅₀	1.2 μM Compound: Sunitinib	Antiproliferative activity against human A498 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human A498 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 36332882]
A498	IC₅₀	1.25 μM Compound: Sunitinib	Cytotoxicity against human A498 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A498 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32947227]
A498	IC₅₀	4.3 μM Compound: Sunitinib	Cytotoxicity against human A498 cells after 72 hrs by MTT assay Cytotoxicity against human A498 cells after 72 hrs by MTT assay	[PMID: 23489626]
A498	IC₅₀	7981 nM Compound: Sunitinib	Antiproliferative activity against human A498 cells after 48 hrs by MTT assay Antiproliferative activity against human A498 cells after 48 hrs by MTT assay	[PMID: 29057042]
A549	IC₅₀	10.14 μM Compound: Sunitinib	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Blue assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Blue assay	[PMID: 32531682]
A549	IC₅₀	11 μM Compound: Sunitinib	Antiproliferative activity against human A549 cells incubated for 2 days by MTT assay Antiproliferative activity against human A549 cells incubated for 2 days by MTT assay	[PMID: 30878834]
A549	IC₅₀	11 μM Compound: Sunitinib	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 30502686]
A549	IC₅₀	12.35 μM Compound: SU-11248	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 22483608]
A549	IC₅₀	14.4 μM Compound: S	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27639369]
A549	IC₅₀	14.4 μM Compound: Sunitinib	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27448916]
A549	IC₅₀	14.4 μM Compound: Sunitinib	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 27397498]
A549	IC₅₀	18.5 μM Compound: 3, SU-11248	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 22019188]
A549	IC₅₀	2.44 μM Compound: Sunitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTS assay Antiproliferative activity against human A549 cells after 72 hrs by MTS assay	[PMID: 27575478]
A549	IC₅₀	2.44 μM Compound: Sunitinib	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23602441]
A549	IC₅₀	22.1 μM Compound: Sunitinib	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
A549	IC₅₀	3.06 μM Compound: Sunitinib	Antiproliferative activity against human Non-small-cell lung cancer A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human Non-small-cell lung cancer A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32531682]
A549	IC₅₀	5.73 μM Compound: Sunitinib	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 36970141]
A549	IC₅₀	6.61 μM Compound: Sunitinib	Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition by MTT assay	10.1007/s00044-012-0170-3
A549	IC₅₀	7.93 μM Compound: Sunitinib	Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by SRB assay	[PMID: 26009164]
A549	IC₅₀	9.1 μM Compound: Sunitinib	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 26920800]
ACHN	IC₅₀	2.5 μM Compound: SUN	Cytotoxicity against human ACHN cells assessed as inhibition of cell viability after 6 days by MTT assay Cytotoxicity against human ACHN cells assessed as inhibition of cell viability after 6 days by MTT assay	[PMID: 23360104]
ACHN	IC₅₀	5.7 μM Compound: Sunitinib	Cytotoxicity against human ACHN cells after 72 hrs by MTT assay Cytotoxicity against human ACHN cells after 72 hrs by MTT assay	[PMID: 23489626]
B16-F10	IC₅₀	15.35 μM Compound: Sunitinib	Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 36970141]
BaF3	IC₅₀	> 10 μM Compound: Sunitinib	Antiproliferative activity against mouse BaF3 cells assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	EC₅₀	> 1000 nM Compound: Sunitinib	Inhibition of human BCR-ABL T315I mutant expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Inhibition of human BCR-ABL T315I mutant expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 27010810]
BaF3	GI₅₀	0.002 μM Compound: 2	Inhibition of Tel-fused cKIT T670I mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT T670I mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	IC₅₀	0.0023 μM Compound: Sunitinib	Antiproliferative activity against mouse BaF3 cells expressing Tel-PDGFRbeta assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing Tel-PDGFRbeta assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	GI₅₀	0.006 μM Compound: 2	Inhibition of Tel-fused cKIT V559D/V654A double mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT V559D/V654A double mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	GI₅₀	0.009 μM Compound: 2	Inhibition of Tel-fused cKIT V559D mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT V559D mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	GI₅₀	0.02 μM Compound: 2	Inhibition of Tel-fused cKIT V654A mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT V654A mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	GI₅₀	0.023 μM Compound: 2	Inhibition of Tel-fused cKIT L567P mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT L567P mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	IC₅₀	0.035 μM Compound: Sunitinib	Antiproliferative activity against mouse BaF3 cells expressing FLT3-ITD assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing FLT3-ITD assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	GI₅₀	0.053 μM Compound: 2	Inhibition of Tel-fused cKIT T670I/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT T670I/V559D double mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	GI₅₀	0.078 μM Compound: 2	Inhibition of Tel-fused cKIT (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	IC₅₀	0.238 μM Compound: Sunitinib	Antiproliferative activity against mouse BaF3 cells expressing Tel-KDR-myc1.3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing Tel-KDR-myc1.3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	IC₅₀	0.297 μM Compound: Sunitinib	Antiproliferative activity against mouse BaF3 cells expressing PTC3-RET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing PTC3-RET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	GI₅₀	0.51 μM Compound: 2	Inhibition of Tel-fused cKIT N822K mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT N822K mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	GI₅₀	1.01 μM Compound: 2	Growth inhibition of mouse BAF3 cells measured after 72 hrs by CCK8 assay Growth inhibition of mouse BAF3 cells measured after 72 hrs by CCK8 assay	[PMID: 31250638]
BaF3	IC₅₀	1.154 μM Compound: Sunitinib	Antiproliferative activity against mouse BaF3 cells expressing NPM-ALK assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing NPM-ALK assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	IC₅₀	1.2 μM Compound: SU-11248	Growth inhibition of mouse BA/F3 cells assessed as incorporation of [3H]thymidine incorporation after 72 hrs by liquid scintillation counting Growth inhibition of mouse BA/F3 cells assessed as incorporation of [3H]thymidine incorporation after 72 hrs by liquid scintillation counting	[PMID: 20117004]
BaF3	IC₅₀	1.289 μM Compound: Sunitinib	Antiproliferative activity against mouse BaF3 cells expressing Tel-IGF-1R assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing Tel-IGF-1R assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	GI₅₀	1.3 nM Compound: Sunitinib	Growth inhibition of mouse BaF3 cells transfected with FLT3-ITD mutation assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Growth inhibition of mouse BaF3 cells transfected with FLT3-ITD mutation assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35923716]
BaF3	GI₅₀	1.38 μM Compound: 2	Inhibition of Tel-fused cKIT D816V mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay Inhibition of Tel-fused cKIT D816V mutant (unknown origin) transfected in mouse BAF3 cells assessed as decrease in cell proliferation after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
BaF3	IC₅₀	1.469 μM Compound: Sunitinib	Antiproliferative activity against mouse BaF3 cells expressing KIT D816V mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing KIT D816V mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	IC₅₀	1.561 μM Compound: Sunitinib	Antiproliferative activity against mouse BaF3 cells expressing Tel-FGFR3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing Tel-FGFR3 assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	GI₅₀	1.6 μM Compound: 2	Cytotoxicity mouse BA/F3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay Cytotoxicity mouse BA/F3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay	[PMID: 27545040]
BaF3	GI₅₀	19.38 nM Compound: Sunitinib	Growth inhibition of mouse BaF3 cells transfected with FLT3-WT-D835H mutation assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Growth inhibition of mouse BaF3 cells transfected with FLT3-WT-D835H mutation assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35923716]
BaF3	GI₅₀	2.3 nM Compound: Sunitinib	Growth inhibition of mouse BaF3 cells transfected with FLT3-WT-D835V mutation assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Growth inhibition of mouse BaF3 cells transfected with FLT3-WT-D835V mutation assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35923716]
BaF3	IC₅₀	3.846 μM Compound: Sunitinib	Antiproliferative activity against mouse BaF3 cells expressing ERBB2 V659E mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing ERBB2 V659E mutant assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	GI₅₀	4.3 nM Compound: Sunitinib	Growth inhibition of mouse BaF3 cells transfected with FLT3-WT-D835N mutation assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Growth inhibition of mouse BaF3 cells transfected with FLT3-WT-D835N mutation assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35923716]
BaF3	GI₅₀	4.789 μM Compound: 2	Cytotoxicity in mouse parental BA/F3 cells incubated for 72 hrs by MTS assay Cytotoxicity in mouse parental BA/F3 cells incubated for 72 hrs by MTS assay	[PMID: 30204441]
BaF3	IC₅₀	5.124 μM Compound: Sunitinib	Antiproliferative activity against mouse BaF3 cells expressing Trp-MET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing Trp-MET assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	GI₅₀	6.5 nM Compound: Sunitinib	Growth inhibition of mouse BaF3 cells transfected with FLT3-WT-D835F mutation assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Growth inhibition of mouse BaF3 cells transfected with FLT3-WT-D835F mutation assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35923716]
BaF3	GI₅₀	6.9 nM Compound: Sunitinib	Growth inhibition of mouse BaF3 cells transfected with FLT3-WT-D835Y mutation assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Growth inhibition of mouse BaF3 cells transfected with FLT3-WT-D835Y mutation assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35923716]
BaF3	GI₅₀	67.8 nM Compound: Sunitinib	Growth inhibition of mouse BaF3 cells transfected with FLT3-ITD-F691L mutation assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Growth inhibition of mouse BaF3 cells transfected with FLT3-ITD-F691L mutation assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35923716]
BaF3	IC₅₀	7.177 μM Compound: Sunitinib	Antiproliferative activity against mouse BaF3 cells expressing Bcr-ABL assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay Antiproliferative activity against mouse BaF3 cells expressing Bcr-ABL assessed as cell growth inhibition measured after 72 hrs by Alamar Blue assay	[PMID: 26629594]
BaF3	GI₅₀	8.7 nM Compound: Sunitinib	Growth inhibition of mouse BaF3 cells transfected with FLT3-ITD-D835Y mutation assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Growth inhibition of mouse BaF3 cells transfected with FLT3-ITD-D835Y mutation assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35923716]
BEAS-2B	IC₅₀	6.09 μM Compound: Sunitinib	Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 36970141]
Bel-7402	EC₅₀	11 μM Compound: Sunitinib	Photocytotoxicity against human Bel7402 cells assessed as cell viability preincubated for 5 hrs with cells followed by UVA-1 irradiation at 3.0 mW/cm'2 for 20 mins measured after 48 hrs by CCK8 assay Photocytotoxicity against human Bel7402 cells assessed as cell viability preincubated for 5 hrs with cells followed by UVA-1 irradiation at 3.0 mW/cm'2 for 20 mins measured after 48 hrs by CCK8 assay	[PMID: 26584085]
Bel-7402	IC₅₀	2.67 μM Compound: Sunitinib	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 24904961]
BT-474	EC₅₀	0.9 μM Compound: Sunitinib	Antiproliferative activity against human BT474 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human BT474 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 30996798]
BT-549	IC₅₀	15.5 μM Compound: S	Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27639369]
BT-549	IC₅₀	15.5 μM Compound: Sunitinib	Cytotoxicity against human BT549 cells after 48 hrs by MTT assay Cytotoxicity against human BT549 cells after 48 hrs by MTT assay	[PMID: 27397498]
BT-549	IC₅₀	15.5 μM Compound: Sunitinib	Cytotoxicity against human BT549 cells after 48 hrs by MTT assay Cytotoxicity against human BT549 cells after 48 hrs by MTT assay	[PMID: 27128173]
BT-549	IC₅₀	15.54 μM Compound: Sunitinib	Cytotoxicity against human BT549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human BT549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27448916]
BT-549	IC₅₀	2.2 μM Compound: Sunitinib(R)	Antiproliferative activity against human BT549 cells expressing NRP1 assessed as cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human BT549 cells expressing NRP1 assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 31699610]
BT-549	IC₅₀	3.5 μM Compound: Sunitinib(R)	Antiproliferative activity against human BT549 cells expressing NRP1 assessed as cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human BT549 cells expressing NRP1 assessed as cell viability measured after 72 hrs by MTT assay	[PMID: 31699610]
BXPC-3	EC₅₀	> 1000 nM Compound: Sunitinib	Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 27010810]
BXPC-3	EC₅₀	2.5 μM Compound: Sunitinib	Antiproliferative activity against human BxPC3 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human BxPC3 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 30996798]
BXPC-3	IC₅₀	3.63 μM Compound: 2	Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 23999040]
CAKI-1	GI₅₀	0.63 μM Compound: NSC 750690	Antiproliferative activity against human CAKI-1 cells after 48 hrs by SRB assay Antiproliferative activity against human CAKI-1 cells after 48 hrs by SRB assay	[PMID: 22560627]
CAKI-1	IC₅₀	4.93 μM Compound: Sunitinib	Cytotoxicity against human CAKI-1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human CAKI-1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32947227]
CAKI-2	EC₅₀	> 1000 nM Compound: Sunitinib	Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay	[PMID: 27010810]
CHO	GI₅₀	2.03 μM Compound: 2	Antiproliferative activity against CHO cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against CHO cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
CHO	IC₅₀	33.4 μM Compound: sunitinib	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
COLO 205	IC₅₀	> 4 μM Compound: 1a	Antiproliferative activity against human COLO205 cells after 72 hrs by MTT assay Antiproliferative activity against human COLO205 cells after 72 hrs by MTT assay	[PMID: 20570526]
COLO 205	IC₅₀	8 μM Compound: Sunitinib	Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay	[PMID: 28756024]
DU-145	IC₅₀	16.3 μM Compound: S	Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27639369]
DU-145	IC₅₀	16.38 μM Compound: Sunitinib	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27448916]
DU-145	IC₅₀	16.4 μM Compound: Sunitinib	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 27397498]
DU-145	IC₅₀	16.4 μM Compound: Sunitinib	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 27128173]
EKVX	GI₅₀	7.9 μM Compound: NSC 750690	Antiproliferative activity against human EKVX cells after 48 hrs by SRB assay Antiproliferative activity against human EKVX cells after 48 hrs by SRB assay	[PMID: 22560627]
GIST430	GI₅₀	2000 nM Compound: 2	Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as cell growth inhibition after 120 hrs by methylene blue staining Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as cell growth inhibition after 120 hrs by methylene blue staining	[PMID: 31721578]
GIST430	GI₅₀	47 nM Compound: Sunitinib	Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as reduction in cell viability by MTS assay Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as reduction in cell viability by MTS assay	[PMID: 30968693]
GIST430	GI₅₀	47 nM Compound: Sunitinib	Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as reduction in cell viability by methylene blue staining based ass Antiproliferative activity against human GIST430 cells harboring c-KIT exon 11 primary in-frame V560-L576 deletion mutant and exon 13 heterozygous secondary missense V654A mutant assessed as reduction in cell viability by methylene blue staining based ass	[PMID: 30968693]
GIST430	GI₅₀	98 nM Compound: 2	Cytotoxicity against human GIST430 cells harboring KIT V654A mutant assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay Cytotoxicity against human GIST430 cells harboring KIT V654A mutant assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay	[PMID: 28991465]
GIST48	GI₅₀	2000 nM Compound: Sunitinib	Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as reduction in cell viability by MTS assay Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as reduction in cell viability by MTS assay	[PMID: 30968693]
GIST48	GI₅₀	2000 nM Compound: Sunitinib	Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as reduction in cell viability by methylene blue staining based assay Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as reduction in cell viability by methylene blue staining based assay	[PMID: 30968693]
GIST48	GI₅₀	47 nM Compound: 2	Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as cell growth inhibition after 120 hrs by methylene blue staining based assay Antiproliferative activity against human GIST48 cells harboring c-KIT exon 11 homozygous primary missense V560D mutant and exon 17 heterozygous secondary D820A mutant assessed as cell growth inhibition after 120 hrs by methylene blue staining based assay	[PMID: 31721578]
GIST882	GI₅₀	0.11 μM Compound: 2	Antiproliferative activity against cKIT dependent human GIST882 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against cKIT dependent human GIST882 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
GIST882	GI₅₀	64 nM Compound: Sunitinib	Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as reduction in cell viability by MTS assay Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as reduction in cell viability by MTS assay	[PMID: 30968693]
GIST882	GI₅₀	64 nM Compound: 2	Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as cell growth inhibition after 144 hrs by methylene blue staining based assay Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as cell growth inhibition after 144 hrs by methylene blue staining based assay	[PMID: 31721578]
GIST882	GI₅₀	64 nM Compound: Sunitinib	Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as reduction in cell viability by methylene blue staining based assay Antiproliferative activity against human GIST882 cells harboring c-KIT exon 13 homozygous primary K642E mutant assessed as reduction in cell viability by methylene blue staining based assay	[PMID: 30968693]
GISTT1	GI₅₀	0.004 μM Compound: 2	Inhibition of c-KIT 560 to 578 deletion/T670I mutant in human GISTT1 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of c-KIT 560 to 578 deletion/T670I mutant in human GISTT1 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31250638]
GISTT1	GI₅₀	0.011 μM Compound: 2	Inhibition of c-KIT 560 to 578 deletion mutant in human GISTT1 cells assessed as growth inhibition after 72 hrs by CCK8 assay Inhibition of c-KIT 560 to 578 deletion mutant in human GISTT1 cells assessed as growth inhibition after 72 hrs by CCK8 assay	[PMID: 31250638]
GISTT1	GI₅₀	0.041 μM Compound: 2	Antiproliferative activity against cKIT dependent human GISTT1 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against cKIT dependent human GISTT1 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
GISTT1	GI₅₀	38 nM Compound: Sunitinib	Antiproliferative activity against human GISTT1 cells harboring heterozygous V560-Y578 deletion mutant assessed as reduction in cell viability by MTS assay Antiproliferative activity against human GISTT1 cells harboring heterozygous V560-Y578 deletion mutant assessed as reduction in cell viability by MTS assay	[PMID: 30968693]
GISTT1	GI₅₀	38 nM Compound: 2	Antiproliferative activity against human GISTT1 cells harboring heterozygous deletion mutation at C-kit exon 11 assessed as cell growth inhibition after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay Antiproliferative activity against human GISTT1 cells harboring heterozygous deletion mutation at C-kit exon 11 assessed as cell growth inhibition after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay	[PMID: 31721578]
GISTT1	GI₅₀	38 nM Compound: Sunitinib	Antiproliferative activity against human GISTT1 cells harboring heterozygous V560-Y578 del mutation assessed as reduction in cell viability by methylene blue staining based assay Antiproliferative activity against human GISTT1 cells harboring heterozygous V560-Y578 del mutation assessed as reduction in cell viability by methylene blue staining based assay	[PMID: 30968693]
GISTT1	GI₅₀	40 nM Compound: 2	Cytotoxicity against human GISTT1 cells assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay Cytotoxicity against human GISTT1 cells assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay	[PMID: 28991465]
GISTT1	GI₅₀	5880 nM Compound: 2	Cytotoxicity against human GISTT1 cells harboring KIT D816E mutant assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay Cytotoxicity against human GISTT1 cells harboring KIT D816E mutant assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay	[PMID: 28991465]
GISTT1	GI₅₀	90 nM Compound: 2	Cytotoxicity against human GISTT1 cells harboring KIT T670I mutant assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay Cytotoxicity against human GISTT1 cells harboring KIT T670I mutant assessed as cell growth inhibition after 72 hrs by CellTiterGlo assay	[PMID: 28991465]
H69AR	IC₅₀	5.8 μM Compound: Sunitinib	Antiproliferative activity against multidrug resistant human NCI-H69AR assessed as inhibition of cell proliferation by MTT assay Antiproliferative activity against multidrug resistant human NCI-H69AR assessed as inhibition of cell proliferation by MTT assay	[PMID: 32531682]
HCT-116	IC₅₀	10.69 μM Compound: Sunitinib	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 36970141]
HCT-116	IC₅₀	18.35 μM Compound: SU-11248	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 22483608]
HCT-116	IC₅₀	4.71 μM Compound: Sunitinib	Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 27575478]
HCT-116	IC₅₀	4.71 μM Compound: Sunitinib	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23602441]
HCT-116	IC₅₀	5.62 μM Compound: Sunitinib	Growth inhibition of human HCT116 cells after 48 hrs by MTT assay Growth inhibition of human HCT116 cells after 48 hrs by MTT assay	[PMID: 27956344]
HCT-116	IC₅₀	5.62 μM Compound: Sunitinib	Antiproliferative activity against human HCT116 cells by MTT assay Antiproliferative activity against human HCT116 cells by MTT assay	[PMID: 30059803]
HCT-116	IC₅₀	6.1 μM Compound: 3, SU-11248	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 22019188]
HEK293	IC₅₀	5 μM Compound: Sunitinib	Antiproliferative activity against HEK293 cells incubated for 2 days by MTT assay Antiproliferative activity against HEK293 cells incubated for 2 days by MTT assay	[PMID: 30878834]
HEK293	IC₅₀	5 μM Compound: Sunitinib	Antiproliferative activity against HEK293 cells by MTT assay Antiproliferative activity against HEK293 cells by MTT assay	[PMID: 30502686]
HEK293	IC₅₀	6.1 μM Compound: Sunitinib	Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay	[PMID: 28230985]
HeLa	EC₅₀	> 10 μM Compound: Sutent	Toxicity in human HeLa cells assessed as cell cycle arrest at G2M phase by flow cytometry based phenotypic drug discovery based assay Toxicity in human HeLa cells assessed as cell cycle arrest at G2M phase by flow cytometry based phenotypic drug discovery based assay	[PMID: 22409666]
HeLa	IC₅₀	> 30 μM Compound: Sunitinib	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by SRB assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by SRB assay	[PMID: 26009164]
HeLa	IC₅₀	10.4 μM Compound: S	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27639369]
HeLa	IC₅₀	7.8 μM Compound: Sunitinib	Antiproliferative activity against human HeLa cells incubated for 2 days by MTT assay Antiproliferative activity against human HeLa cells incubated for 2 days by MTT assay	[PMID: 30878834]
HeLa	IC₅₀	7.8 μM Compound: Sunitinib	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 30502686]
HepG2	IC₅₀	13.24 μM Compound: SU-11248	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22483608]
HepG2	IC₅₀	13.6 μM Compound: sunitinib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25064347]
HepG2	IC₅₀	15.4 μM Compound: 3, SU-11248	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22019188]
HepG2	IC₅₀	16.06 μM Compound: Sunitinib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28057423]
HepG2	IC₅₀	16.06 μM Compound: Sunitinib	Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability after 48 hrs by SRB assay	[PMID: 26009164]
HepG2	IC₅₀	3.81 μM Compound: 1a	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 20570526]
HepG2	IC₅₀	5.61 μM Compound: 2	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 23999040]
HepG2	IC₅₀	7.78 μM Compound: Sunitinib	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 30059803]
HK-2	IC₅₀	5.85 μM Compound: Sunitinib	Antiproliferative activity against human HK2 cells after 72 hrs by MTT assay Antiproliferative activity against human HK2 cells after 72 hrs by MTT assay	[PMID: 24904961]
HL-60	GI₅₀	0.001 μM Compound: 2	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
HL-60	IC₅₀	15.5 μM Compound: 3, SU-11248	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 22019188]
HL-60	IC₅₀	21.5 μM Compound: Sunitinib	Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
HL-60	IC₅₀	3.53 μM Compound: Sunitinib	Cytotoxicity against Homo sapiens (human) HL60 cells assessed as growth inhibition by MTT assay Cytotoxicity against Homo sapiens (human) HL60 cells assessed as growth inhibition by MTT assay	10.1007/s00044-012-0170-3
HL-60	IC₅₀	36.8 nM Compound: Sunitinib	Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25089810]
HL-60	IC₅₀	4.95 μM Compound: Sunitinib	Cytotoxicity against human HL60 cells after 72 hrs by CCK-8 assay Cytotoxicity against human HL60 cells after 72 hrs by CCK-8 assay	[PMID: 27643639]
HL-60	IC₅₀	7 μM Compound: Sunitinib	Antiproliferative activity against human HL60 cells by MTT assay Antiproliferative activity against human HL60 cells by MTT assay	[PMID: 30502686]
HL-60	IC₅₀	8.7 μM Compound: Sunitinib	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 36332882]
HMEC-1	IC₅₀	7 μM Compound: Sunitinib	Antiproliferative activity against HMEC1 cells incubated for 2 days by MTT assay Antiproliferative activity against HMEC1 cells incubated for 2 days by MTT assay	[PMID: 30878834]
HMEC-1	IC₅₀	7 μM Compound: Sunitinib	Antiproliferative activity against HMEC1 cells by MTT assay Antiproliferative activity against HMEC1 cells by MTT assay	[PMID: 30502686]
HMEC-1	IC₅₀	7 μM Compound: Sunitinib	Antiangiogenic activity against HMEC1 cells after 20 hrs by tube formation assay Antiangiogenic activity against HMEC1 cells after 20 hrs by tube formation assay	[PMID: 30502686]
HT-29	IC₅₀	0.33 μM Compound: Sunitinib, SU11248	Cytotoxicity against VEGFR expressing human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against VEGFR expressing human HT-29 cells after 72 hrs by MTT assay	[PMID: 23131541]
HT-29	IC₅₀	0.33 μM Compound: SU11248	Antiproliferative activity against human HT-29 cells expressing VEGFR after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells expressing VEGFR after 72 hrs by MTT assay	[PMID: 22444679]
HT-29	IC₅₀	1.3 μM Compound: Sunitinib	Cytotoxicity against human HT-29 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 21621880]
HT-29	IC₅₀	1.47 μM Compound: 2	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 23999040]
HT-29	GI₅₀	1.6 μM Compound: NSC 750690	Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay	[PMID: 22560627]
HT-29	IC₅₀	1.7 μM Compound: Sunitinib	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 26920800]
HT-29	IC₅₀	10.34 μM Compound: Sunitinib	Antiproliferative activity against human HT-29 cells assessed as inhibition of VEGF-induced cell proliferation measured after 24 hrs by CCK8 assay Antiproliferative activity against human HT-29 cells assessed as inhibition of VEGF-induced cell proliferation measured after 24 hrs by CCK8 assay	[PMID: 33340911]
HT-29	IC₅₀	3.8 μM Compound: Sunitinib	Antiproliferative activity against human HT-29 cells incubated for 2 days by MTT assay Antiproliferative activity against human HT-29 cells incubated for 2 days by MTT assay	[PMID: 30878834]
HT-29	IC₅₀	3.8 μM Compound: Sunitinib	Antiproliferative activity against human HT-29 cells by MTT assay Antiproliferative activity against human HT-29 cells by MTT assay	[PMID: 30502686]
HT-29	IC₅₀	4.7 μM Compound: Sunitinib	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by SRB assay	[PMID: 26009164]
Huh-7	CC₅₀	246 μM Compound: Sunitinib	Cytotoxicity against human HuH7 cells infected with DENV2 New Guinea C by microplate alamar blue assay Cytotoxicity against human HuH7 cells infected with DENV2 New Guinea C by microplate alamar blue assay	[PMID: 31136173]
Huh-7	IC₅₀	3.03 μM Compound: Sunitinib	Growth inhibition of human HuH7 cells after 48 hrs by MTT assay Growth inhibition of human HuH7 cells after 48 hrs by MTT assay	[PMID: 27956344]
Huh-7	IC₅₀	3.03 μM Compound: Sunitinib	Antiproliferative activity against human HuH7 cells by MTT assay Antiproliferative activity against human HuH7 cells by MTT assay	[PMID: 30059803]
Huh-7	IC₅₀	4707 nM Compound: Sunitinib	Antiproliferative activity against human HuH7 cells after 48 hrs by MTT assay Antiproliferative activity against human HuH7 cells after 48 hrs by MTT assay	[PMID: 29057042]
HUVEC	IC₅₀	> 3 μM Compound: Sunitinib	Antiproliferative activity against bFGF-stimulated HUVEC cells assessed as cell growth inhibition measured after 24 hrs by BrdUrd incorporation based spectrophotometric analysis Antiproliferative activity against bFGF-stimulated HUVEC cells assessed as cell growth inhibition measured after 24 hrs by BrdUrd incorporation based spectrophotometric analysis	[PMID: 26629594]
HUVEC	IC₅₀	0.12 μM Compound: Sunitinib	Inhibition of VEGF-A induced HUVEC cell sprouting after 24 hrs by angiogenesis assay Inhibition of VEGF-A induced HUVEC cell sprouting after 24 hrs by angiogenesis assay	[PMID: 21741249]
HUVEC	IC₅₀	0.546 μM Compound: Sunitinib	Antiangiogenic activity in HUVEC assessed as inhibition of VEGF-induced capillary tube formation after 8 hrs by matrigel based inverted microscopic analysis Antiangiogenic activity in HUVEC assessed as inhibition of VEGF-induced capillary tube formation after 8 hrs by matrigel based inverted microscopic analysis	[PMID: 29057052]
HUVEC	IC₅₀	0.8 μM Compound: Sunitinib	Antiangiogenic activity in HUVEC assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiangiogenic activity in HUVEC assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 27176944]
HUVEC	IC₅₀	1.5 μM Compound: Sunitinib	Anti-angiogenesis activity in HUVEC assessed as inhibition of VEGF-induced tube formation incubated for 6 hrs by capillary tube formation assay Anti-angiogenesis activity in HUVEC assessed as inhibition of VEGF-induced tube formation incubated for 6 hrs by capillary tube formation assay	[PMID: 32892623]
HUVEC	IC₅₀	2.1 μM Compound: Sunitinib	Antiangiogenic activity in HUVEC assessed as inhibition of VEGF-induced capillary tube formation incubated for 6 hrs by capillary tube formation assay Antiangiogenic activity in HUVEC assessed as inhibition of VEGF-induced capillary tube formation incubated for 6 hrs by capillary tube formation assay	[PMID: 35294831]
HUVEC	IC₅₀	2.54 μM Compound: Sunitinib	Antivascular activity against HUVEC assessed as inhibition of tube formation incubated for 6 hrs by inverted microscopy Antivascular activity against HUVEC assessed as inhibition of tube formation incubated for 6 hrs by inverted microscopy	[PMID: 33902285]
HUVEC	IC₅₀	2.75 μM Compound: Sunitinib	Cytotoxicity against VEGF-stimulated HUVECs assessed as growth inhibition by MTT assay Cytotoxicity against VEGF-stimulated HUVECs assessed as growth inhibition by MTT assay	10.1007/s00044-012-0170-3
HUVEC	IC₅₀	2.75 μM Compound: Su11248	Inhibition of VEGF-induced cell proliferation in HUVEC by MTT assay Inhibition of VEGF-induced cell proliferation in HUVEC by MTT assay	[PMID: 21450463]
HUVEC	IC₅₀	3 μM Compound: Sunitinib	Antiproliferative activity against HUVEC after 48 hrs by MTT assay Antiproliferative activity against HUVEC after 48 hrs by MTT assay	[PMID: 29482944]
HUVEC	IC₅₀	3.2 μM Compound: Sunitinib	Antiproliferative activity against HUVEC after 48 hrs by MTT assay Antiproliferative activity against HUVEC after 48 hrs by MTT assay	[PMID: 30384047]
HUVEC	IC₅₀	3.63 μM Compound: Sunitinib	Antiangiogenic activity against VEGF-induced HUVEC assessed as inhibition of cell proliferation preincubated for 30 mins followed by VEGF addition measured after 24 hrs by MTT assay Antiangiogenic activity against VEGF-induced HUVEC assessed as inhibition of cell proliferation preincubated for 30 mins followed by VEGF addition measured after 24 hrs by MTT assay	[PMID: 31295714]
HUVEC	IC₅₀	3.9 μM Compound: Sunitinib	Cytotoxicity against HUVECs assessed as growth inhibition by MTT assay Cytotoxicity against HUVECs assessed as growth inhibition by MTT assay	10.1007/s00044-012-0170-3
HUVEC	IC₅₀	4.04 μM Compound: Sunitinib	Cytotoxicity against recombinant Homo sapiens (human) basic FGF-stimulated HUVECs assessed as growth inhibition by MTT assay Cytotoxicity against recombinant Homo sapiens (human) basic FGF-stimulated HUVECs assessed as growth inhibition by MTT assay	10.1007/s00044-012-0170-3
HUVEC	IC₅₀	4.04 μM Compound: Su11248	Inhibition of bFGF-induced cell proliferation in HUVEC by MTT assay Inhibition of bFGF-induced cell proliferation in HUVEC by MTT assay	[PMID: 21450463]
HUVEC	IC₅₀	53 nM Compound: SU-11248	Inhibition of KDR autophosphorylation in HUVEC by Western blot analysis Inhibition of KDR autophosphorylation in HUVEC by Western blot analysis	[PMID: 20833039]
HUVEC	IC₅₀	6.36 μM Compound: Sunitinib	Antiproliferative activity against HUVEC after 48 hrs by MTT assay Antiproliferative activity against HUVEC after 48 hrs by MTT assay	[PMID: 29587221]
HUVEC	IC₅₀	6.37 μM Compound: Sunitinib	Cytotoxicity against HUVEC cells assessed as inhibition of cell proliferation in presence of VEGF measured after 24 hrs by CCK8 assay Cytotoxicity against HUVEC cells assessed as inhibition of cell proliferation in presence of VEGF measured after 24 hrs by CCK8 assay	[PMID: 33340911]
HUVEC	IC₅₀	6.46 μM Compound: Sunitinib	Antiangiogenic activity against HUVEC assessed as inhibition of cell proliferation measured after 30 mins by MTT assay Antiangiogenic activity against HUVEC assessed as inhibition of cell proliferation measured after 30 mins by MTT assay	[PMID: 31295714]
HUVEC	EC₅₀	645 nM Compound: SU 011248, Sutent	Antiangiogenic activity in HUVEC assessed as inhibition of VEGF-induced tube formation after 24 hrs by phalloidin-sulforhodamine staining method Antiangiogenic activity in HUVEC assessed as inhibition of VEGF-induced tube formation after 24 hrs by phalloidin-sulforhodamine staining method	[PMID: 23583911]
HUVEC	IC₅₀	7 nM Compound: Sunitinib	Antiproliferative activity against VEGF-stimulated HUVEC cells assessed as cell growth inhibition measured after 24 hrs by BrdUrd incorporation based spectrophotometric analysis Antiproliferative activity against VEGF-stimulated HUVEC cells assessed as cell growth inhibition measured after 24 hrs by BrdUrd incorporation based spectrophotometric analysis	[PMID: 26629594]
HUVEC	IC₅₀	9.92 μM Compound: Sunitinib	Growth inhibition of HUVEC after 24 hrs in presence of VEGF by MTT assay Growth inhibition of HUVEC after 24 hrs in presence of VEGF by MTT assay	[PMID: 29057052]
IM-9	IC₅₀	1.35 μM Compound: Sunitinib	Cytotoxicity against Homo sapiens (human) IM9 cells assessed as growth inhibition by MTT assay Cytotoxicity against Homo sapiens (human) IM9 cells assessed as growth inhibition by MTT assay	10.1007/s00044-012-0170-3
Jurkat	IC₅₀	> 1 μM Compound: SU	Cytotoxicity in human Jurkat cells assessed as inhibition of cellular viability after 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity in human Jurkat cells assessed as inhibition of cellular viability after 72 hrs by CellTiter-Glo luminescent assay	[PMID: 30742435]
Jurkat	IC₅₀	8.5 μM Compound: Sunitinib	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
K562	GI₅₀	1 μM Compound: 2	Antiproliferative activity against BCR-ABL dependent human K562 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against BCR-ABL dependent human K562 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
K562	EC₅₀	12.5 μM Compound: 6	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 24 hrs by cell-titer glo assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 24 hrs by cell-titer glo assay	[PMID: 32334266]
K562	IC₅₀	14 μM Compound: Sunitinib	Cytotoxicity against human K562 cells after 24 hrs by MTT assay Cytotoxicity against human K562 cells after 24 hrs by MTT assay	[PMID: 28756024]
K562	IC₅₀	2.41 μM Compound: Sunitinib	Cytotoxicity against Homo sapiens (human) K562 cells assessed as growth inhibition by MTT assay Cytotoxicity against Homo sapiens (human) K562 cells assessed as growth inhibition by MTT assay	10.1007/s00044-012-0170-3
K562	IC₅₀	21.9 μM Compound: 3, SU-11248	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 22019188]
K562	IC₅₀	5.8 μM Compound: Sunitinib	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 36332882]
K562	EC₅₀	7.03 μM Compound: 6	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by celltox-green assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by celltox-green assay	[PMID: 32334266]
K562	EC₅₀	7.23 μM Compound: 6	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 32334266]
Kasumi 1	IC₅₀	0.016 μM Compound: 1a	Antiproliferative activity against human Kasumi-1 cells after 72 hrs by MTT assay Antiproliferative activity against human Kasumi-1 cells after 72 hrs by MTT assay	[PMID: 20570526]
Kasumi 1	IC₅₀	15 nM Compound: SU-11248	Inhibition of c-Kit autophosphorylation in human Kasumi-1 cells by Western blot analysis Inhibition of c-Kit autophosphorylation in human Kasumi-1 cells by Western blot analysis	[PMID: 20833039]
KB 3-1	IC₅₀	2.3 μM Compound: sunitinib	Cytotoxicity against human P-gp-negative KB-3-1 cells after 72 hrs by MTT assay Cytotoxicity against human P-gp-negative KB-3-1 cells after 72 hrs by MTT assay	[PMID: 19397322]
KB-V1	IC₅₀	4.1 μM Compound: sunitinib	Cytotoxicity against human P-glycoprotein-expressing KBV1 cells after 72 hrs by MTT assay Cytotoxicity against human P-glycoprotein-expressing KBV1 cells after 72 hrs by MTT assay	[PMID: 19397322]
KU812 cell line	GI₅₀	1.1 μM Compound: 2	Antiproliferative activity against BCR-ABL dependent human KU812 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against BCR-ABL dependent human KU812 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
L02	IC₅₀	19.93 μM Compound: Sunitinib	Antiproliferative activity against human LO2 cells after 72 hrs by MTT assay Antiproliferative activity against human LO2 cells after 72 hrs by MTT assay	[PMID: 24904961]
L02	IC₅₀	4.62 μM Compound: Sunitinib	Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay	[PMID: 27643639]
L02	IC₅₀	75.6 μM Compound: sunitinib	Antiproliferative activity against human L02 cells after 48 hrs by MTT assay Antiproliferative activity against human L02 cells after 48 hrs by MTT assay	[PMID: 25064347]
Leukemia cell	IC₅₀	0.03 μM Compound: 3, SU-11248	Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing wild type FLT3 assessed as cell viability after 72 hrs by luciferase assay Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing wild type FLT3 assessed as cell viability after 72 hrs by luciferase assay	[PMID: 22221201]
Leukemia cell	IC₅₀	0.03 μM Compound: 3, SU-11248	Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing FLT3-ITD mutation assessed as cell viability after 72 hrs by luciferase assay Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing FLT3-ITD mutation assessed as cell viability after 72 hrs by luciferase assay	[PMID: 22221201]
Leukemia cell	IC₅₀	1.1 μM Compound: 3, SU-11248	Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing FLT3-D835Y mutation assessed as cell viability after 72 hrs by luciferase assay Cytotoxicity against human primary leukemia cells isolated from acute myeloid leukemia patient expressing FLT3-D835Y mutation assessed as cell viability after 72 hrs by luciferase assay	[PMID: 22221201]
LNCaP	IC₅₀	12.61 μM Compound: S	Cytotoxicity against human LNCAP cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human LNCAP cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27210438]
MCF7	IC₅₀	0.08 μM Compound: Sunitinib	Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay Antiproliferative activity against human MCF7 cells incubated for 2 days by MTT assay	[PMID: 30878834]
MCF7	IC₅₀	0.08 μM Compound: Sunitinib	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 30502686]
MCF7	EC₅₀	0.96 μM Compound: Sunitinib	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 30996798]
MCF7	IC₅₀	10.5 μM Compound: sunitinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25064347]
MCF7	GI₅₀	2 μM Compound: NSC 750690	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 22560627]
MCF7	IC₅₀	23.76 μM Compound: S	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27210438]
MCF7	IC₅₀	23.8 μM Compound: Sunitinib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27448916]
MCF7	IC₅₀	25.41 μM Compound: Sunitinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28057423]
MCF7	IC₅₀	25.41 μM Compound: Sunitinib	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by SRB assay	[PMID: 26009164]
MCF7	IC₅₀	6.29 μM Compound: Sunitinib	Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 27575478]
MCF7	IC₅₀	6.29 μM Compound: Sunitinib	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23602441]
MCF7	IC₅₀	6.8 μM Compound: Sunitinib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
MDA-MB-231	EC₅₀	> 1000 nM Compound: Sunitinib	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 27010810]
MDA-MB-231	IC₅₀	2.6 μM Compound: Sunitinib(R)	Antiproliferative activity against human MDA-MB-231 cells expressing NRP1 assessed as cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells expressing NRP1 assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 31699610]
MDA-MB-231	IC₅₀	3.7 μM Compound: Sunitinib(R)	Antiproliferative activity against human MDA-MB-231 cells expressing NRP1 assessed as cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells expressing NRP1 assessed as cell viability measured after 72 hrs by MTT assay	[PMID: 31699610]
MDA-MB-231	IC₅₀	3.7 μM Compound: Sunitinib	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 21621880]
MDA-MB-231	IC₅₀	32 μM Compound: Sunitinib	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 28756024]
MDA-MB-231	IC₅₀	4.51 μM Compound: Sunitinib	Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition by MTT assay Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition by MTT assay	10.1007/s00044-012-0170-3
MDA-MB-231	IC₅₀	6 μM Compound: Sunitinib	Anticancer activity against human MDA-MB-231 cells after 48 hrs by XTT assay Anticancer activity against human MDA-MB-231 cells after 48 hrs by XTT assay	[PMID: 28325600]
MDA-MB-231	IC₅₀	6.98 μM Compound: Sunitinib	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28760313]
MDA-MB-231	IC₅₀	7.4 μM Compound: S	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27639369]
MDA-MB-231	IC₅₀	7.4 μM Compound: Sunitinib	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 27397498]
MDA-MB-231	IC₅₀	7.4 μM Compound: Sunitinib	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 27128173]
MDA-MB-231	IC₅₀	7.44 μM Compound: Sunitinib	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27448916]
MDA-MB-435	GI₅₀	2 μM Compound: NSC 750690	Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by SRB assay	[PMID: 22560627]
MDA-MB-435	IC₅₀	9.3 μM Compound: Sunitinib	Cytotoxicity against human MDA-MB-435 cells by MTT assay Cytotoxicity against human MDA-MB-435 cells by MTT assay	[PMID: 26920800]
MEG-01	GI₅₀	1.2 μM Compound: 2	Antiproliferative activity against human BCR-ABL dependent MEG01 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against human BCR-ABL dependent MEG01 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
MKN-45	IC₅₀	9.25 μM Compound: Sunitinib	Antiproliferative activity against human MKN-45 cells assessed assessed as inhibition of VEGF-induced cell proliferation measured after 24 hrs by CCK8 assay Antiproliferative activity against human MKN-45 cells assessed assessed as inhibition of VEGF-induced cell proliferation measured after 24 hrs by CCK8 assay	[PMID: 33340911]
MOLM-13	EC₅₀	14.3 nM Compound: 6	Cytotoxicity against human MOLM-13 cells assessed as cell viability measured after 72 hrs by MTS assay Cytotoxicity against human MOLM-13 cells assessed as cell viability measured after 72 hrs by MTS assay	[PMID: 32334266]
MOLM-13	IC₅₀	17.7 nM Compound: Sunitinib	Cytotoxicity against human MOLM13 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MOLM13 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25089810]
MOLM-13	GI₅₀	54 nM Compound: 2	Antiproliferative activity against human MOLM13 harboring FLT3-ITD mutant assessed as cell growth inhibition after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay Antiproliferative activity against human MOLM13 harboring FLT3-ITD mutant assessed as cell growth inhibition after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay	[PMID: 31721578]
MOLM-13	IC₅₀	69.6 nM Compound: Sunitinib	Antiproliferative activity against human MOLM-13 cells incubated for 72 hrs by Cell Counting Kit-8 assay Antiproliferative activity against human MOLM-13 cells incubated for 72 hrs by Cell Counting Kit-8 assay	[PMID: 33797247]
MOLM-14	GI₅₀	0.005 μM Compound: 2	Antiproliferative activity against FLT3-ITD dependent human MOLM14 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against FLT3-ITD dependent human MOLM14 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
MONO-MAC-6	IC₅₀	5.7 μM Compound: Sunitinib	Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
MV4-11	IC₅₀	< 0.01 μM Compound: Sunitinib	Antiproliferative activity against human MV4-11 cells after 72 hrs by Celltiter-Glo luminescent cell viability assay Antiproliferative activity against human MV4-11 cells after 72 hrs by Celltiter-Glo luminescent cell viability assay	[PMID: 29935772]
MV4-11	GI₅₀	0.001 μM Compound: 2	Antiproliferative activity against FLT3-ITD dependent human MV4-11 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against FLT3-ITD dependent human MV4-11 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
MV4-11	IC₅₀	0.003 μM Compound: Sunitinib	Antiproliferative activity against human MV411 cells after 48 hrs by MTT assay Antiproliferative activity against human MV411 cells after 48 hrs by MTT assay	[PMID: 24904961]
MV4-11	IC₅₀	0.003 μM Compound: Sunitinib	Cytotoxicity against FLT3-dependent human MV4-11 cells after 72 hrs by MTT assay Cytotoxicity against FLT3-dependent human MV4-11 cells after 72 hrs by MTT assay	[PMID: 22452518]
MV4-11	IC₅₀	0.009 μM Compound: 1a	Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay	[PMID: 20570526]
MV4-11	IC₅₀	24.3 nM Compound: Sunitinib	Cytotoxicity against human MV4-11 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25089810]
MV4-11	IC₅₀	31.5 nM Compound: Sunitinib	Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by Cell Counting Kit-8 assay Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by Cell Counting Kit-8 assay	[PMID: 33797247]
MV4-11	IC₅₀	38.5 nM Compound: Sunitinib	Antiproliferative activity against human MV4-11 cells harboring FLT3 ITD mutant after 72 hrs by MTS assay Antiproliferative activity against human MV4-11 cells harboring FLT3 ITD mutant after 72 hrs by MTS assay	[PMID: 28038328]
MV4-11	IC₅₀	4.3 nM Compound: sunitinib	Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer-blue cell viability assay Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer-blue cell viability assay	[PMID: 19754199]
MV4-11	IC₅₀	4.3 nM Compound: Sunitinib	Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay Cytotoxicity against human MV4-11 cells after 72 hrs by cell titer-blue assay	[PMID: 19654408]
MV4-11	IC₅₀	54 nM Compound: SU	Cytotoxicity in human MV4-11 cells assessed as inhibition of cellular viability incubated for 72 hrs by CellTiter-Blue assay Cytotoxicity in human MV4-11 cells assessed as inhibition of cellular viability incubated for 72 hrs by CellTiter-Blue assay	[PMID: 30742435]
MV4-11	IC₅₀	8 nM Compound: Sunitinib	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay	[PMID: 32659083]
MV4-11	IC₅₀	9 nM Compound: SU-11248	Cytotoxicity against human MV4-11 cells by MTT assay Cytotoxicity against human MV4-11 cells by MTT assay	[PMID: 20833039]
NCI-H1299	EC₅₀	1.54 μM Compound: Sunitinib	Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 30996798]
NCI-H1975	EC₅₀	> 1000 nM Compound: Sunitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay	[PMID: 27010810]
NCI-H3122	IC₅₀	0.83 μM Compound: Sunitinib	Antiproliferative activity against human NCI-H3122 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H3122 cells after 72 hrs by MTT assay	[PMID: 24904961]
NCI-H460	IC₅₀	> 4 μM Compound: 1a	Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay	[PMID: 20570526]
NCI-H460	IC₅₀	2.7 μM Compound: Sunitinib	Cytotoxicity against human H460 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human H460 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 21621880]
NCI-H460	IC₅₀	4.31 μM Compound: Sunitinib	Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay	[PMID: 24904961]
NCI-H526	IC₅₀	1.01 μM Compound: Sunitinib	Antiproliferative activity against human NCI-H526 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H526 cells after 72 hrs by MTT assay	[PMID: 24904961]
NCI-H727	IC₅₀	10120 nM Compound: Sunitinib	Antiproliferative activity against human NCI-H727 cells after 48 hrs by MTT assay Antiproliferative activity against human NCI-H727 cells after 48 hrs by MTT assay	[PMID: 29057042]
NIH3T3	IC₅₀	18 nM Compound: SU-11248	Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr	[PMID: 16162008]
OCI-AML-5	IC₅₀	14 nM Compound: Sunitinib	Antiproliferative activity against human OCI-AML5 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay Antiproliferative activity against human OCI-AML5 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay	[PMID: 32659083]
OVCAR-3	GI₅₀	3.2 μM Compound: NSC 750690	Antiproliferative activity against human OVCAR3 cells after 48 hrs by SRB assay Antiproliferative activity against human OVCAR3 cells after 48 hrs by SRB assay	[PMID: 22560627]
PA-1	IC₅₀	7.97 μM Compound: S	Cytotoxicity against human PA1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human PA1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27210438]
PANC-1	EC₅₀	13 μM Compound: Sunitinib	Photocytotoxicity against human PANC1 cells assessed as cell viability preincubated for 5 hrs with cells followed by UVA-1 irradiation at 3.0 mW/cm'2 for 20 mins measured after 48 hrs by CCK8 assay Photocytotoxicity against human PANC1 cells assessed as cell viability preincubated for 5 hrs with cells followed by UVA-1 irradiation at 3.0 mW/cm'2 for 20 mins measured after 48 hrs by CCK8 assay	[PMID: 26584085]
PANC-1	IC₅₀	14.94 μM Compound: Sunitinib	Cytotoxicity against human PANC1 cells assessed as inhibition of cell viability after 48 hrs by SRB assay Cytotoxicity against human PANC1 cells assessed as inhibition of cell viability after 48 hrs by SRB assay	[PMID: 26009164]
PBMC	IC₅₀	46.3 μM Compound: Sunitinib	Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
PC-3	EC₅₀	> 1000 nM Compound: Sunitinib	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 27010810]
PC-3	IC₅₀	12.6 μM Compound: S	Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27639369]
PC-3	IC₅₀	19.6 μM Compound: Sunitinib	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27448916]
PC-3	IC₅₀	19.6 μM Compound: Sunitinib	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 27128173]
PC-3	IC₅₀	25.1 μM Compound: 3, SU-11248	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 22019188]
PC-3	IC₅₀	55.6 μM Compound: Sunitinib	Cytotoxicity against human PC3 cells by MTT assay Cytotoxicity against human PC3 cells by MTT assay	[PMID: 26920800]
PC-9	IC₅₀	10.97 μM Compound: SU-11248	Cytotoxicity against human PC9 cells after 48 hrs by MTT assay Cytotoxicity against human PC9 cells after 48 hrs by MTT assay	[PMID: 22483608]
RCC4	IC₅₀	4 μM Compound: Sunitinib	Anticancer activity against human RCC4 cells after 48 hrs by XTT assay Anticancer activity against human RCC4 cells after 48 hrs by XTT assay	[PMID: 28325600]
Rec1	GI₅₀	0.87 μM Compound: 2	Antiproliferative activity against human Rec1 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against human Rec1 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
RS4-11	IC₅₀	1 μM Compound: 1a	Antiproliferative activity against human RS4:11 cells after 72 hrs by MTT assay Antiproliferative activity against human RS4:11 cells after 72 hrs by MTT assay	[PMID: 20570526]
RS4-11	IC₅₀	16 nM Compound: SU-11248	Inhibition of FLT3 autophosphorylation in human RS4-11 cells by Western blot analysis Inhibition of FLT3 autophosphorylation in human RS4-11 cells by Western blot analysis	[PMID: 20833039]
RS4-11	IC₅₀	34 nM Compound: Sunitinib	Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay Inhibition of FLT3 ITD mutant autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay	[PMID: 19654408]
RS4-11	IC₅₀	9.9 nM Compound: Sunitinib	Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay Inhibition of FLT3 autophosphorylation in human RS4-11 cells after 2 hrs by electrochemiluminescence assay	[PMID: 19654408]
RWPE-1	IC₅₀	23 μM Compound: S	Cytotoxicity against human RWPE1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human RWPE1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27210438]
RWPE-1	IC₅₀	23 μM Compound: Sunitinib	Cytotoxicity against human RWPE1 cells after 48 hrs by MTT assay Cytotoxicity against human RWPE1 cells after 48 hrs by MTT assay	[PMID: 27128173]
RWPE-1	IC₅₀	25.2 μM Compound: S	Cytotoxicity against human RWPE1 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human RWPE1 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27639369]
SF-539	IC₅₀	12.2 μM Compound: 4	Inhibition of PDGFRbeta tyrosine kinase activity in PDGF-BB-stimulated human SF-539 cells after 60 mins by ELISA Inhibition of PDGFRbeta tyrosine kinase activity in PDGF-BB-stimulated human SF-539 cells after 60 mins by ELISA	[PMID: 22204741]
SF-539	IC₅₀	12.2 μM Compound: 4	Inhibition of PDGFRbeta phosphorylation in human SF539 cells after 10 mins by FLISA Inhibition of PDGFRbeta phosphorylation in human SF539 cells after 10 mins by FLISA	[PMID: 20403700]
SF-539	IC₅₀	83.1 μM Compound: Sunitinib	Inhibition of PDGFRbeta in human SF539 cells assessed as inhibition of PDGFR-BB-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA Inhibition of PDGFRbeta in human SF539 cells assessed as inhibition of PDGFR-BB-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA	[PMID: 23434139]
SF-539	IC₅₀	83.1 μM Compound: SU11248	Inhibition of PDGFRbeta in human SF539 cells pretreated for 60 mins measured after 1 hr by ELISA Inhibition of PDGFRbeta in human SF539 cells pretreated for 60 mins measured after 1 hr by ELISA	[PMID: 22739090]
SF-539	IC₅₀	83.1 μM Compound: 4	Inhibition of PDGF-BB-induced PDGFR beta phosphorylation in human SF539 cells overexpressing PDGFR beta pretreated for 60 mins prior to PDGF-BB addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis Inhibition of PDGF-BB-induced PDGFR beta phosphorylation in human SF539 cells overexpressing PDGFR beta pretreated for 60 mins prior to PDGF-BB addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis	[PMID: 23375090]
Sf9	IC₅₀	3021 nM Compound: Sunitinib	Inhibition of ATP-activated recombinant human N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) expressed in baculovirus infected Sf9 insect cells assessed as decrease in poly (Glu,Tyr) 4:1 phosphorylation incubated for 3 Inhibition of ATP-activated recombinant human N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) expressed in baculovirus infected Sf9 insect cells assessed as decrease in poly (Glu,Tyr) 4:1 phosphorylation incubated for 3	[PMID: 30968693]
Sf9	IC₅₀	31 nM Compound: 2	Inhibition of wild type recombinant GST-tagged FLT3 (Y567 to S993 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using Her2 peptide as substrate measured after 4 hrs in presence of ATP by Kinase-Glo Plus reagent-based lumine Inhibition of wild type recombinant GST-tagged FLT3 (Y567 to S993 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells using Her2 peptide as substrate measured after 4 hrs in presence of ATP by Kinase-Glo Plus reagent-based lumine	[PMID: 31721578]
Sf9	IC₅₀	48 nM Compound: 2	Inhibition of recombinant N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) (unknown origin) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr) 4:1 as substrate measured after 150 mins in presence of Inhibition of recombinant N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) (unknown origin) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr) 4:1 as substrate measured after 150 mins in presence of	[PMID: 31721578]
Sf9	IC₅₀	48 nM Compound: Sunitinib	Inhibition of recombinant human N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) expressed in baculovirus infected Sf9 insect cells assessed as decrease in poly (Glu,Tyr) 4:1 phosphorylation measured after 150 mins in pr Inhibition of recombinant human N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) expressed in baculovirus infected Sf9 insect cells assessed as decrease in poly (Glu,Tyr) 4:1 phosphorylation measured after 150 mins in pr	[PMID: 30968693]
Sf9	IC₅₀	80 nM Compound: Sunitinib	Inhibition of unactivated recombinant human N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) expressed in baculovirus infected Sf9 insect cells assessed as decrease in poly (Glu,Tyr) 4:1 phosphorylation incubated for 30 Inhibition of unactivated recombinant human N-terminal 6x-His-tagged c-KIT (547 to 935 residues)/(694 to 753 residues deletion) expressed in baculovirus infected Sf9 insect cells assessed as decrease in poly (Glu,Tyr) 4:1 phosphorylation incubated for 30	[PMID: 30968693]
SH-SY5Y	IC₅₀	83.1 nM Compound: Sunitinib	Inhibition of PDGFRbeta in human SH-SY5Y cells by phosphotyrosine ELISA assay Inhibition of PDGFRbeta in human SH-SY5Y cells by phosphotyrosine ELISA assay	[PMID: 24890652]
SK-MEL-28	IC₅₀	4.13 μM Compound: Sunitinib	Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 36970141]
SK-OV-3	EC₅₀	1.36 μM Compound: Sunitinib	Antiproliferative activity against human SKOV3 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human SKOV3 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 30996798]
SK-OV-3	IC₅₀	9.21 μM Compound: Sunitinib	Cytotoxicity against human SKOV3 cells assessed as inhibition of cell viability after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as inhibition of cell viability after 48 hrs by SRB assay	[PMID: 26009164]
SMMC-7721	IC₅₀	6.47 μM Compound: Sunitinib	Cytotoxicity against human SMMC7721 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 21621880]
SNB-19	GI₅₀	10 μM Compound: NSC 750690	Antiproliferative activity against human SNB19 cells after 48 hrs by SRB assay Antiproliferative activity against human SNB19 cells after 48 hrs by SRB assay	[PMID: 22560627]
SW-620	GI₅₀	1.3 μM Compound: NSC 750690	Antiproliferative activity against human SW620 cells after 48 hrs by SRB assay Antiproliferative activity against human SW620 cells after 48 hrs by SRB assay	[PMID: 22560627]
SW-620	IC₅₀	6.25 μM Compound: Sunitinib	Growth inhibition of human SW620 cells after 48 hrs by MTT assay Growth inhibition of human SW620 cells after 48 hrs by MTT assay	[PMID: 27956344]
SW-620	IC₅₀	6.25 μM Compound: Sunitinib	Antiproliferative activity against human SW620 cells by MTT assay Antiproliferative activity against human SW620 cells by MTT assay	[PMID: 30059803]
SW982	IC₅₀	41.2 μM Compound: Sunitinib	Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
T-24	IC₅₀	2.44 μM Compound: 2	Antiproliferative activity against human T24 cells after 72 hrs by MTT assay Antiproliferative activity against human T24 cells after 72 hrs by MTT assay	[PMID: 23999040]
THP-1	IC₅₀	> 1 μM Compound: SU	Cytotoxicity in human THP1 cells assessed as inhibition of cellular viability after 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity in human THP1 cells assessed as inhibition of cellular viability after 72 hrs by CellTiter-Glo luminescent assay	[PMID: 30742435]
THP-1	IC₅₀	0.5 μM Compound: 1a	Antiproliferative activity against human THP1 cells after 72 hrs by MTT assay Antiproliferative activity against human THP1 cells after 72 hrs by MTT assay	[PMID: 20570526]
THP-1	IC₅₀	14.9 μM Compound: Sunitinib	Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
THP-1	IC₅₀	45.7 nM Compound: Sunitinib	Cytotoxicity against human THP1 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25089810]
TK-10	GI₅₀	6.3 μM Compound: NSC 750690	Antiproliferative activity against human TK10 cells after 48 hrs by SRB assay Antiproliferative activity against human TK10 cells after 48 hrs by SRB assay	[PMID: 22560627]
TT	IC₅₀	0.04 μM Compound: Sunitinib	Antiproliferative activity against human TT cells pretreated for 72 hrs followed by compound-washout measured after 72 hrs by MTT assay Antiproliferative activity against human TT cells pretreated for 72 hrs followed by compound-washout measured after 72 hrs by MTT assay	[PMID: 24904961]
U-251	IC₅₀	18.9 nM Compound: Sunitinib	Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method	[PMID: 25882519]
U-251	IC₅₀	18.9 nM Compound: sunitinib	Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA	[PMID: 24900865]
U-251	IC₅₀	18.9 nM Compound: Sunitinib	Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay	[PMID: 24890652]
U-251	IC₅₀	18.9 μM Compound: 4	Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA	[PMID: 22204741]
U-251	IC₅₀	18.9 μM Compound: Sunitinib	Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA	[PMID: 23434139]
U-251	IC₅₀	18.9 μM Compound: SU11248	Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA	[PMID: 22739090]
U-251	IC₅₀	18.9 μM Compound: 4	Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA	[PMID: 20403700]
U-251	IC₅₀	18.9 μM Compound: 4	Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis	[PMID: 23375090]
U-251	IC₅₀	83.1 nM Compound: Sunitinib	Inhibition of PDGFR-beta in human U251 cells compound pretreated for 60 min before PDGF-BB stimulation for 10 mins by phosphotyrosine ELISA cytoblot method Inhibition of PDGFR-beta in human U251 cells compound pretreated for 60 min before PDGF-BB stimulation for 10 mins by phosphotyrosine ELISA cytoblot method	[PMID: 25882519]
U-87MG ATCC	IC₅₀	59.75 μM Compound: S	Cytotoxicity against human U87MG cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87MG cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27210438]
U-937	IC₅₀	> 5 μM Compound: 1a	Antiproliferative activity against human U937 cells after 72 hrs by MTT assay Antiproliferative activity against human U937 cells after 72 hrs by MTT assay	[PMID: 20570526]
U-937	GI₅₀	1.7 μM Compound: 2	Antiproliferative activity against human U937 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay Antiproliferative activity against human U937 cells assessed as reduction in cell viability after 72 hrs by celltiter-glo/CCK8 assay	[PMID: 27077705]
U-937	IC₅₀	13.7 μM Compound: Sunitinib	Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
UACC-257	GI₅₀	4 μM Compound: NSC 750690	Antiproliferative activity against human UACC257 cells after 48 hrs by SRB assay Antiproliferative activity against human UACC257 cells after 48 hrs by SRB assay	[PMID: 22560627]
WI-38	IC₅₀	8.56 μM Compound: Sunitinib	Cytotoxicity against human WI38 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human WI38 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 21621880]

体外研究
(In Vitro)

Sunitinib Malate 也是 KIT 和 FLT-3 的良好抑制剂^[1]。在 RS4;11 细胞 (FLT3-WT) 中，用 Sunitinib (SU11248) 治疗以剂量依赖性方式抑制 FLT3-WT 磷酸化，IC₅₀ 约为 250 nM。在表达 FLT3-ITD 的 MV4;11 细胞中，Sunitinib 以剂量依赖性方式抑制 FLT3-ITD 磷酸化，2 小时治疗后的 IC₅₀ 为 50 nM^[3]。在生化测定中，Sunitinib 对 Flk-1 和 PDGFRβ 表现出竞争性抑制（就 ATP 而言），K_i 值分别为 9 nM 和 8 nM。Sunitinib 也是一种竞争性 FGFR1 酪氨酸激酶活性抑制剂，尽管效力较低，其 K_i 值为 0.83 μM。除了这三种结构相关的分裂激酶结构域 RTK 外，Sunitinib 的活性还针对一系列其他酪氨酸和丝氨酸/苏氨酸激酶进行了评估。在这些生化测定中，Sunitinib 的 IC₅₀ 值通常比 Flk-1 和 PDGFR 的 IC₅₀ 值至少高 10 倍（例如，IC₅₀值为：EGFR 和 Cdk2 >10 μM；Met 为 4 μM；IGFR-1 为 2.4 μM；Abl 为 0.8 μM；Src 为 0.6 μM）^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Sunitinib Malate 口服生物利用度极高，对多种临床前肿瘤模型均有高效治疗作用，有效剂量下耐受性良好^[1]。Sunitinib (80 mg/kg/天) 可抑制无胸腺小鼠体内已建立的 SF763T 和 Colo205 肿瘤异种移植瘤的生长。Sunitinib 治疗可有效抑制已建立的肿瘤异种移植瘤的生长^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

398.47

Formula

C₂₂H₂₇FN₄O₂

CAS 号

557795-19-4

性状

固体

颜色

Yellow to orange

中文名称

舒尼替尼；苏尼替尼

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 20.83 mg/mL (52.27 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.5096 mL	12.5480 mL	25.0960 mL
5 mM	0.5019 mL	2.5096 mL	5.0192 mL
10 mM	0.2510 mL	1.2548 mL	2.5096 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.11 mg/mL (2.79 mM); 澄清溶液

此方案可获得 ≥ 1.11 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 11.1 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 1.11 mg/mL (2.79 mM); 澄清溶液

此方案可获得 ≥ 1.11 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 11.1 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 98.96%

选择批次：

Data Sheet (649 KB) SDS (418 KB)

COA (286 KB) RP-HPLC (187 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Sun L, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003 Mar 27;46(7):1116-9. [Content Brief]

[2]. Ali MM, et al. Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J. 2011 Mar 2;30(5):894-905. [Content Brief]

[3]. O'Farrell AM, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003 May 1;101(9):3597-605. [Content Brief]

[4]. Mendel DB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Can [Content Brief]

Cell Assay ^[3]	RS4;11 and MV4;11 cell lines are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib (1 nM, 5 nM, 10 nM, 25 nM, 75 nM, 100 nM, 250 nM, 500 nM) and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay in triplicate for each condition, as described by the manufacturer. Trypan blue cell viability assays are performed in parallel and yielded similar results^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]^[4]	Mice^[2] Female nu/nu mice (8-12 weeks old, 25 grams) are used. Briefly, 3-5×10⁶ tumor cells are implanted s.c. into the hind flank region of mice on day 0. Daily treatment of tumor-bearing mice with oral administration of Sunitinib as a carboxymethyl cellulose suspension or as a citrate buffered (pH 3.5) solution is initiated once the tumors reached the indicated average size. Tumor growth is evaluated based on twice-weekly measurement of tumor volume. Typically, studies are terminated when tumors in vehicle-treated animals reach an average size of 1000 mm³ or when the tumors are judged to adversely effect the well being of the animals. Rats^[4] Adult male Wistar rats (325-349 g) are used. To validate the ability of the time-lapse imaging method to evaluate the anti-angiogenic effects for a given drug treatment, two drug studies are conducted. In the first study, mesenteric windows are harvested from adult male Wistar rats and cultured for 3 days according to the two experimental groups: 1) 10% serum (n=8 tissues from 4 rats), and 2) 10% serum+Sunitinib (5 μM; n=8 tissues from 4 rats). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Sun L, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003 Mar 27;46(7):1116-9. [Content Brief] [2]. Ali MM, et al. Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J. 2011 Mar 2;30(5):894-905. [Content Brief] [3]. O'Farrell AM, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003 May 1;101(9):3597-605. [Content Brief] [4]. Mendel DB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Can [Content Brief]

Sunitinib 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.5096 mL	12.5480 mL	25.0960 mL	62.7400 mL
	5 mM	0.5019 mL	2.5096 mL	5.0192 mL	12.5480 mL
	10 mM	0.2510 mL	1.2548 mL	2.5096 mL	6.2740 mL
	15 mM	0.1673 mL	0.8365 mL	1.6731 mL	4.1827 mL
	20 mM	0.1255 mL	0.6274 mL	1.2548 mL	3.1370 mL
	25 mM	0.1004 mL	0.5019 mL	1.0038 mL	2.5096 mL
	30 mM	0.0837 mL	0.4183 mL	0.8365 mL	2.0913 mL
	40 mM	0.0627 mL	0.3137 mL	0.6274 mL	1.5685 mL
	50 mM	0.0502 mL	0.2510 mL	0.5019 mL	1.2548 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Sunitinib (Synonyms: 舒尼替尼; SU 11248)

Customer Review

Other Forms of Sunitinib:

MCE 顾客使用本产品发表的 58 篇科研文献

Sunitinib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 VEGFR 亚型特异性产品:

查看 PDGFR 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Sunitinib 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Sunitinib (Synonyms: 舒尼替尼; SU 11248)

Customer Review

Other Forms of Sunitinib:

Sunitinib 相关抗体

MCE 顾客使用本产品发表的 58 篇科研文献

Sunitinib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 VEGFR 亚型特异性产品:

查看 PDGFR 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Sunitinib 相关抗体:

摩尔计算器

稀释计算器

Sunitinib 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z